Navigation Links
Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal

SOUTH PLAINFIELD, N.J., July 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal. The published three-month data showed that treatment with ataluren resulted in statistically significant improvements in chloride channel activity, CF-related cough and positive trends in lung function.


"These encouraging data demonstrating statistically significant pharmacodynamic activity support the potential of ataluren for a significant subset of severely affected CF patients," stated Professor Michael Wilschanski, Director, Pediatric Gastroenterology, Hadassah University Hospital. "The results are important because they suggest that ataluren promotes the production of full-length, functional cystic fibrosis transmembrane conductance regulator (CFTR) protein and addresses the underlying cause of the disorder. Currently available treatments for cystic fibrosis only address symptoms, and new therapies such as ataluren are urgently needed."

Patients with CF lack adequate levels of the CFTR protein, a chloride channel necessary for the normal function of the lungs, pancreas, liver and other organs. In nmCF, an interruption in the genetic code—known as a nonsense mutation—prematurely halts the synthesis of CFTR, causing the protein to be short and non-functioning. Nonsense mutations are categorized as Class I mutations that result in little or no production of the CFTR protein. CF patients with Class I mutations typically experience more severe disease symptoms than those with lower-risk genotypes, including a greater than twofold increased risk of death(1), a higher probability of end-stage lung disease(2), and a higher prevalence of pancreatic insufficiency.(2) It is estimated that nonsense mutations are the cause of CF in about 10% of patients. Ataluren, a protein restoration therapy, is designed to overcome the nonsense mutation and enable the production of a full-length, functional CFTR protein. A genetic test can determine if a patient's disease is caused by a nonsense mutation.

"The results from this study strongly support the conduct of longer term studies to evaluate the clinical benefit of ataluren for patients with nonsense mutation cystic fibrosis," said Robert Spiegel, M.D., Chief Medical Officer of PTC Therapeutics. "A 48-week placebo-controlled Phase 3 study of ataluren in nonsense mutation cystic fibrosis is fully enrolled and we look forward to the availability of data in the first half of 2012."


The Phase 2 clinical trial (Study 005e) was an extension of a previously conducted short-term open-label Phase 2a proof-of-concept trial (Study 005) of ataluren in adults with nmCF. Study 005e enrolled 19 patients, aged 19 years and older, who received one of two ataluren doses three times per day (morning, midday and evening) for 12 weeks (84 days). On-treatment clinic visits were conducted every 28 days, with an additional follow-up clinic visit at Day 112. The study was conducted at the Hadassah Hebrew University Hospital in Jerusalem, Israel and sponsored by PTC Therapeutics.

The study's primary endpoint was CFTR chloride channel activity as assessed by nasal transepithelial potential difference (NPD). A response was predefined as an improvement of at least -5.0 mV from baseline in total chloride transport. The results showed that ataluren induced statistically significant improvements in chloride channel activity at each dose level and for all patients combined. The aggregate mean change in total chloride transport for all patients was -5.4 mV (p<0.001).

Secondary endpoints of lung function included evaluations of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). At day 84, the aggregate mean change from baseline for all patients was 4.5% and 3.5% for relative percent predicted FEV1 and FVC, respectively. Importantly, combined mean improvements in FEV1 and FVC occurred coincident with the greatest mean improvement in total chloride transport and, with the cessation of ataluren treatment, FEV1 and FVC values reverted towards baseline. The study was not powered to detect statistical significance in these outcome measures and observed changes were not statistically significant.

As an additional secondary endpoint, the study evaluated the frequency of CF-related coughing, which is the most common complaint among patients and often interferes with activities of daily living.(3),(4) During the study, quantitative measurements of CF-related coughing were conducted over a 24-hour period after each clinic visit and results showed that ataluren was associated with an aggregate mean reduction in waking cough frequency of 23% for all patients (p=0.006, paired t-test).

Safety results from the study showed that ataluren was generally well tolerated. Most adverse events were mild or moderate and compliance with study drug was greater than 96% for all patients.

The abstract titled "Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis" is available online at:


An investigational new drug discovered by PTC Therapeutics, ataluren (formerly referred to as PTC124®) is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. A nonsense mutation is an alteration in the genetic code that prematurely halts the synthesis of an essential protein. The resulting disorder is determined by which protein cannot be expressed in its entirety and is no longer functional, such as the CFTR protein in nonsense mutation cystic fibrosis.

The development of ataluren has been supported by grants from Cystic Fibrosis Foundation Therapeutics, Inc. (the nonprofit affiliate of the Cystic Fibrosis Foundation); FDA's Office of Orphan Products Development; Muscular Dystrophy Association; National Center for Research Resources; National Heart, Lung, and Blood Institute; and Parent Project Muscular Dystrophy. The FDA and the European Commission have granted ataluren Orphan Drug status for the treatment of nonsense mutation cystic fibrosis and nonsense mutation Duchenne and Becker muscular dystrophy. The FDA has also granted ataluren Subpart E designation for expedited development, evaluation, and marketing for CF and dystrophinopathy and Fast Track designation for the development of treatment for nonsense mutation dystrophinopathy.


PTC Therapeutics has an exclusive collaboration with Genzyme Corporation for the development and commercialization of ataluren. PTC Therapeutics will commercialize ataluren in the United States and Canada, while Genzyme will commercialize the product in other regions of the world.


CF is a life-threatening genetic disorder that causes serious lung infections and digestive complications. The predicted median age of survival for a person with CF is about 37 years.  According to the Cystic Fibrosis Foundation, CF affects approximately 30,000 adults and children in the United States and nearly 70,000 people worldwide. Genetic testing is required to confirm a complete diagnosis and to determine if a patient's disease is caused by a nonsense mutation. It is estimated that nonsense mutations are the cause of CF in about 10 percent of patients in the United States and Europe and over 50 percent of patients in Israel. Available treatments for CF are designed to alleviate symptoms rather than correct the underlying cause of the disease. Based on the current standard of care, the treatment burden for CF patients is high and, on average, adults with CF take 7 daily therapies. More information regarding CF is available through the Cystic Fibrosis Foundation (


The Hadassah University Medical Center is a leading provider of medical and health services in Israel, known for its pioneering vision and enduring commitment to patient-centered care and groundbreaking research. Incorporating all medical and surgical sub-specialties, its 800-bed Ein Kerem tertiary care hospital, 300-bed Mt. Scopus community hospital and satellite sites serve more than 1 million people a year from throughout Jerusalem, Israel and the Middle East.

The Hadassah University Medical Center is the flagship project of Hadassah, the Women's Zionist Organization of America, Inc.


PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology, and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and are the basis for collaborations with leading biopharmaceutical companies. For more information, visit the company's web site at


(1) McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest 2006 Nov;130(5):1441-7.

(2) de Gracia J., Mata F, Alvarez A, Casals T, Gatner S, Vendrell M, de la RD, Guarner L, Hermosilla E. Genotype-phenotype correlation for pulmonary function in cystic fibrosis. Thorax 2005 Jul;60(7):558-63.

(3) Sawicki GS, Sellers DE, Robinson WM. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage 2008; 35(4): 372-80.

(4) VanDevanter DR, Rasouliyan L, Murphy TM, et al. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol 2008; 43(8):739-44.

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
2. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
3. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
4. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
5. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
6. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
7. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
8. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
9. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
Post Your Comments:
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market ... companies have joined forces, resulting in the founding of Pharma To ... Pharma To Market are pleased to announce their expansion into ... in Singapore . The company are delighted to ... Co-Director of the Singapore based entity. Joelle ...
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
Breaking Medicine Technology:
(Date:2/24/2017)... Lawn, NJ (PRWEB) , ... February 24, 2017 ... ... with robust marketing services, which specializes in thought leadership , media relations, ... marketing campaigns and services that will be powered through Act-On, an intuitive marketing ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... announced an official 2017 partnership with The Jensie Gran Fondo of Marin. For ... and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael ... “Mama June: From Not to Hot,” which will begin airing on February 24, 2017. ... to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... National Institute for Health and Care Excellence (NICE) framework. The agreement allows ... Service (NHS) to search, order and purchase medical and healthcare-related content through ...
Breaking Medicine News(10 mins):